Treatment Resistant Depression
213
45
65
77
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
35 trials with published results (16%)
Research Maturity
77 completed trials (36% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
5.6%
12 terminated out of 213 trials
86.5%
+0.0% vs benchmark
16%
34 trials in Phase 3/4
45%
35 of 77 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 77 completed trials
Clinical Trials (213)
Natural History of Depression, Bipolar Disorder and Suicide Risk
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
Epidural Cortical Stimulation for Depression
Belief Updating in Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
KET-RO Plus RO DBT for Treatment Resistant Depression
Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation
Minocycline as Adjunctive Treatment for Treatment Resistant Depression
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Psilocybin for Treatment-Resistant Depression in Autism
Personalized Therapeutic Neuromodulation for Anhedonic Depression
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Neurofeedback for Treatment Resistant Depression
N2O for Acute Suicidality and Depression in the ED